The FDA stated that Philip Morris International (PMI) can continue marketing IQOS, highlighting that switching completely from cigarettes “substantially reduces your body’s exposure to harmful or potentially harmful chemicals.”
Even if each country decides how to handle public health, EU law has long insisted that goods legally sold in one country must be able to cross borders. This changed under France’s new rule, as it makes a regulated product illegal as soon as it sets foot in the country.
Importantly, this was not a symbolic gesture or political compromise. MRTP authorization is among the most demanding public health pathways in the world, demanding comprehensive toxicological analysis, behavioural data, population modeling, and evidence demonstrating that the product benefits public health as a whole.
Yet despite this, many health entities and lawmakers continue to frame heated tobacco products and other non-combustible nicotine products, such as vapes, as no different from cigarettes. If smokers are repeatedly told that all nicotine products are equally harmful, many will see little reason to switch away from cigarettes. That outcome directly conflicts with public health goals aimed at reducing smoking-related disease. The debate is not theoretical. The body of real-world evidence from countries that embraced harm reduction approaches continues to grow.
Numbers don’t lie
Research published in BMJ Tobacco Control shows that after heated tobacco products entered the Japanese market late in 2014, cigarette sales fell off significantly faster than before. The introduction of heated tobacco led to a reduction in combustible cigarette sales, with some estimates showing declines of over 40% within 3 years. This is one of the largest reductions in smoking ever seen in a developed country without prohibitionist measures.
Importantly, the growth of heated tobacco products seems to be largely among current smokers looking for alternatives and not from nicotine-naive users. This is also seen in the UK vaping experience, with nearly all adult users being current or previous smokers.
Nonetheless, sizable segments of the public health community continue to demand that “more research is necessary” before regulators should recognize harm reduction. Although long-term monitoring is appropriate, critics say such a demand has increasingly become a political tool rather than a scientific benchmark. As if no public health intervention is ever launched with decades of epidemiological certainty already attached to it!
Asking for data that is already widely available
Some harm reduction advocates are also questioning the role of institutional incentives in forming opposition to safer nicotine products. Large advocacy organizations dependent on anti-tobacco funding streams may find it hard to adjust to an environment in which nicotine use evolves away from combustible smoking. If smoking rates collapse because consumers adopt significantly lower-risk products, traditional abstinence-only approaches risk becoming increasingly disconnected from real-world outcomes.
Science or ideology?
The FDA’s latest decision signals that regulatory science is moving toward a more balanced, evidence-based framework—one that recognizes the importance of relative risk in public health. The wider question is whether policymakers and public health institutions worldwide are willing to follow the evidence, or whether ideological resistance will continue to obstruct one of the most promising harm-reduction opportunities in modern tobacco control.
